Thus we provide evidence of an additional receptor, sortilin, to the general M6PR in ECs cells for the delivery of therapeutic recombinant α-Gal A in Fabry disease and potentially other lysosomal storage disorders. This evidence concerns the gene SORT1 and lysosomal storage disease.